Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Atara Biotherapeutics
Atara Biotherapeutics is developing transformative off-the-shelf therapies for serious diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Lassen Therapeutics
Lassen Therapeutics is a developer of antibody biotherapeutics, improving the lives of patients with serious diseases.
Sector
Subsector
Location
total rounds
total raised
Pandion Therapeutics
Pandion Therapeutics develops novel therapeutics for autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Alentis Therapeutics
ALENTIS Therapeutics develops new therapies for advanced liver disease and cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds13
Number of Funding Rounds
Money Raised
Their latest funding was raised on 17.01.2024. Their latest round Post-IPO Equity
Hercules Capital
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors12
Number of lead investors
Number of investors
Amgen Ventures
Amgen Ventures is a biotech-focused venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Marvin Caruthers
Marvin Caruthers, Ph.D., is a Distinguished Professor of Chemistry and Biochemistry at the University of Colorado and a pioneer in the biotechnology field. One of the co-founders of Amgen and Applied Biosystems, Caruthers’ groundbreaking scientific research in nucleic acid chemistry led to the development of DNA synthesizing techniques that remain the industry standard today. Caruthers holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Biochemistry from Northwestern University. A Guggenheim Fellow, he is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Caruthers was awarded the National Medal of Science for 2006, the nation’s highest distinction honoring scientific achievement.
current job
Broadview Ventures
Broadview Ventures invests in technology solutions for cardiovascular and neurovascular diseases.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Thomas E. Hughes
Dr. Hughes has over 25 years of experience in pharmaceutical research and development. Dr. Hughes joined Zafgen in 2008 as president, chief executive officer and a member of the company’s board of directors. From 1987 to 2008, Dr. Hughes held several positions at Novartis AG (and formerly Sandoz Pharmaceuticals) including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles he oversaw many drug discovery and development projects targeting obesity, diabetes, and heart disease. As a scientist, Dr. Hughes led Novartis’ efforts to discover and develop its dipeptidylpeptidase IV inhibitor vildagliptin (Galvus®/Eucreas®), a drug used for the treatment of type 2 diabetes, currently approved in 70 countries. Dr. Hughes is the author of over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity. Dr. Hughes also serves as a director on the board of Miragen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures and Nimbus Discovery, LLC.
current job
Remeditex Ventures
Remeditex invests in innovative early-stage projects with commercialization potential.
Sector
Subsector
Location
count Of Investments
count Of Exists
Dennis Keith Stone
Dennis has served as a member of the Board of Directors since September 2002. Dennis is Chief Scientific Officer and a Director of Remeditex Ventures LLC. He joined Remeditex in August 2011 from UT Southwestern Medical Center, or UTSW, where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development for UTSW from 1998 until July 2011. He has served on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., and MacroGenics, Inc. In addition, he served as the Chairman of the UT Regents’ Technology Transfer Commission, and he was vice chairman of the board of the Texas Emerging Technology Fund’s Life Science Commercialization Center. He received his undergraduate training at The University of Texas at Austin and his medical degree from UTSW.
current job
Acquisitions2
Viridian Therapeutics acquired by Viridian Therapeutics
acquirer
date
type
Viridian Therapeutics
Viridian Therapeutics develops new treatments for underserved diseases in biotechnology.
Sector
Subsector
Keywords
Location
total rounds
total raised
Signal Genetics acquired by Viridian Therapeutics
acquirer
date
type
price
Signal Genetics
Signal Genetics, Inc. is a molecular diagnostics company that provides innovative diagnostic services for cancer patients.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders2
William Marshall
William S. Marshall, Ph.D., is miRagen’s President, Chief Executive Officer, Co-Founder and Director. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates. Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.
current job
organization founded
William Marshall
Eric Newell Olson
Eric Newell Olson, Ph.D. is Professor and Chairman of the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas. One of the world’s leading experts in developmental biology of the heart, Dr. Olson currently holds the Robert A. Welch Distinguished Chair in Science, the Annie and Willie Nelson Professorship in Stem Cell Research, and the Pogue Distinguished Chair in Research on Cardiac Birth Defects at UTSWMC. Prior to his appointment in Dallas, Dr. Olson was both a professor of Biochemistry and Molecular Biology as well as Chemistry at the M.D. Anderson Cancer Center in Houston. He holds BA, Ph.D. and honorary doctorate degrees from Wake Forest University in Winston-Salem, NC. Dr. Olson has received numerous domestic and international awards from organizations such as the American Heart Association, the National Institutes of Health, and Columbia and McGill Universities among others. He is a fellow of the American Academy of Arts and Sciences, the U.S. National Academy of Sciences, and the Institute of Medicine of the National Academy of Sciences Dr. Olson seves on numerous Editorial Boards and scientific societies. In 1996, he was founder of Myogen, Inc., a company that was acquired in 2006 by Gilead Sciences.
current job
organization founded
Eric Newell Olson
Employee Profiles17
Scotty Sengsavang
Vp, product and strategy team leader
Paul Rubin
Executive Vice-President of Research and Development
Activity
Recent News16
The graph reveals the ratio (%) of positive news articles in a chosen time range